cancer immunotherapy: the lmct experienceoco.vub.ac.be/wp-content/uploads/2016/03/lmct.pdf ·...
TRANSCRIPT
![Page 1: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/1.jpg)
Cancer Immunotherapy: the LMCT experience
Kris Thielemans
Karine Breckpot
09.11.2017-ORC – slide 1
![Page 2: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/2.jpg)
The Research Program
09.11.2017-ORC – slide 2
![Page 3: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/3.jpg)
The team and its context
09.11.2017-ORC – slide 3
![Page 4: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/4.jpg)
The team and its context
09.11.2017-ORC – slide 4
![Page 5: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/5.jpg)
The team and its context
09.11.2017-ORC – slide 5
![Page 6: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/6.jpg)
The LMCT team
Gender Female to male ratio ±2
Nationalities: 10 Countries: Belgium, China,
Cuba, Germany, Italy,Mexico, Nigeria, Poland,Spain, the Netherlands
09.11.2017-ORC – slide 6
![Page 7: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/7.jpg)
The LMCT output: last 5 years
10
LMCT-members
GRADUATEDin the last 5 years
continued as
POST-
DOCTORAL
FELLOW1PROFESSIONAL PRESENTATIONS
> 150 (inter)national seminars,
conferences and symposia
> 20 news featureson topics such as treatment of melanoma, dendritic
cell vaccines, mRNA vaccines, lentiviral vectors and
nanobodies for tumor targeting
88 SCIENTIFIC PAPERS
09.11.2017-ORC – slide 7
![Page 8: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/8.jpg)
The LMCT output
> 15 patents
5 clinical studies for the treatment
of melanoma, myeloma and hepato-
cellular carcinoma patients
The spin-off eTheRNA Immuno-
therapies NV was founded in 2013
(http://www.etherna.be)
09.11.2017-ORC – slide 8
![Page 9: Cancer Immunotherapy: the LMCT experienceoco.vub.ac.be/wp-content/uploads/2016/03/LMCT.pdf · Cancer Immunotherapy: the LMCT experience Kris Thielemans Karine Breckpot 09.11.2017-ORC](https://reader033.vdocuments.mx/reader033/viewer/2022052005/6019719a7d894865ec46a43b/html5/thumbnails/9.jpg)
09.11.2017-ORC – slide 9